Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
5G-EMERALD: Amivantamab in High Grade Malignant Brain Tumours
NCT06632236Phase 1Active, not recruiting
- Sponsor
- The Institute of Cancer Research
- Start
- Oct 2024
- Primary completion
- Jul 2027
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of amivantamab in glioblastoma (GBM), astrocytoma and diffuse hemispheric glioma (DHG), sponsored by The Institute of Cancer Research. Primary endpoints: Safety and Tolerability at 18 months and Preliminary Antitumour Activity at 18 months. Started Oct 2024; status: active, not recruiting.
02
Drugs
amivantamab
03
Conditions
glioblastoma (GBM)astrocytomadiffuse hemispheric glioma (DHG)
Beyond the preview
Go deeper on NCT06632236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06632236.